Pfizer’s drug pair cut the risk of prostate cancer worsening or death by 52% in a trial. FDA approved earlier use.
Pfizer’s drug pair cut the risk of prostate cancer worsening or death by 52% in a trial. FDA approved earlier use. Stock Titan
Covered in this story
Analyst targets on Pfizer
- Bank of America: $28.3 → $29 by Oct 2027 · Neutral via TIKR.com
- Cantor Fitzgerald: $28.3 → $28 by Oct 2027 · Neutral via TIKR.com
- JPMorgan: $28.3 → $30 by Oct 2027 · Neutral via The Globe and Mail
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $PFE yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Pfizer →Dalsna Finance is currently tracking 52 stories mentioning Pfizer, the earliest published 18 Jun 2026.
Summary aggregated from Stock Titan's public RSS feed. The full reporting belongs to Stock Titan — please read it on their site.